Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

280.98 +0.79 (+0.28%)
Streaming Delayed Price Updated: 11:13 AM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
56 57 Next >
2 Dividend Growth Stocks to Buy Right Now
A wise man once said, be greedy when others are fearful. 
Via The Motley Fool
Check Out What Whales Are Doing With AMGN
 
Via Benzinga
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Amgen Unusual Options Activity
 
Via Benzinga
3 Quality Dividend Stocks For A Bear Market
The potential for a recession means investors should focus on quality dividend stocks with strong yields. 
Via Talk Markets
Topics Economy
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
 
Via Benzinga
2 Top Dividend Stocks to Buy in September
These two blue-chip dividend stocks have stood the test of time. 
Via The Motley Fool
How Is The Market Feeling About Amgen?
 
Via Benzinga
8 Analysts Have This to Say About Amgen
 
Via Benzinga
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners. 
Via InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has  
Via Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However,... 
Via Benzinga
3 Growth Stocks to Buy in September
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings 
Via MarketBeat
Topics Economy
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
 
Via Benzinga
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
On Friday, the U.S. 
Via Benzinga
Should You Still Buy the Dow Jones' Best-Performing August Stocks?
They're rolling now, but this market has been too hot-and-cold of late to ignore any company's -- or company's stock's -- underlying bigger picture. 
Via The Motley Fool
Topics Stocks
The 3 Most Promising Dow Stocks to Own Now
The Dow market leaders got their heads handed to them in August. Here are three must-own Dow stocks to own for the long haul. 
Via InvestorPlace
Topics Stocks
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
Tesla unveiled an updated Model 3, but also slashed Model S, X prices. 
Via Investor's Business Daily
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
The U.S. Federal Trade Commission (FTC) has approved drug manufacturer Amgen Inc (NASDAQ: AMGN) to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP).  
Via Benzinga
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
The deal can now close in the fourth quarter. 
Via Investor's Business Daily
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
From Horizon Therapeutics plc and Amgen
Via Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Is This the Green Light Biotech Stocks Have Been Waiting For?
It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics. 
Via The Motley Fool
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
To gain an edge, this is what you need to know today. 
Via Benzinga
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.